Esperion Therapeutics Inc (ESPR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Esperion Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
52-Week Range
Current price 3.20 $ — 70% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 74.8% passed
- More than 10% revenue growth is expected for the coming year 35.3% passed
- Share count grows by less than 3% a year 46.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 18.0% failed
- Gross margin at 40% or higher and without meaningful erosion 68.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 6.0 x EBITDA failed
- Operating cash flow covers the profits of the last three years 111 m failed
- Return on capital at 15% or higher, or up versus two years ago 36.5% passed
- Insiders hold at least 10% or are net buyers 0.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.21 | -0.21 – -0.21 | 338 | -90.9% | 1 |
| 12/31/2027 | 0.26 | 0.09 – 0.49 | 439 | 222.6% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.02 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.11 | – | 69 | 114.30 | -30.80 | -35 | -35 |
| 2025: Q1 | -0.21 | -164.10 | 65 | -52.80 | -62.20 | -23 | -23 |
| 2025: Q2 | -0.06 | – | 82 | 11.60 | -15.40 | -31 | -31 |
| 2025: Q3 | -0.16 | – | 87 | 69.10 | -35.90 | -4 | -4 |
| 2025: Q4 | 0.22 | – | 168 | 143.70 | 36.70 | 45 | 45 |
| 2026: Q1 | -0.10 | – | 80 | 23.20 | -31.50 | -28 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -76 | -75 | -3.33 | -48 | 229 | 245 |
| 2017 | 0 | -169 | -167 | -6.98 | -131 | 245 | 278 |
| 2018 | 184 | -205 | -202 | -7.54 | -149 | -598 | 143 |
| 2019 | 148 | -93 | -97 | -3.59 | -70 | 20 | 214 |
| 2020 | 228 | -121 | -144 | -5.23 | -85 | -96 | 353 |
| 2021 | 78 | -227 | -269 | -9.31 | -264 | -197 | 382 |
| 2022 | 75 | -180 | -234 | -3.52 | -175 | -324 | 248 |
| 2023 | 116 | -156 | -209 | -2.03 | -135 | -455 | 206 |
| 2024 | 332 | 54 | -52 | -0.28 | -24 | -389 | 344 |
| 2025 | 403 | 60 | -23 | -0.11 | -13 | -302 | 466 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Esperion Therapeutics, Inc., ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Medikamente zur Behandlung von Patienten mit erhöhtem LDL-Cholesterin (LDL-C) in den USA.
| Employees | 294 |
|---|---|
| Headquarters | Ann Arbor, MI |
| Address | 3891 Ranchero Drive, 48108 Ann Arbor, United States |
| Phone | 734 887 3903 |
| Website | esperion.com |
| IPO Date | 26. Jun 2013 |
| ISIN | US29664W1053 |
| Stock Split | 1:6.986 on 06/11/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Benjamin Halladay M.B.A. | Chief Financial Officer | 1986 |
| John B. Harlow Jr. | Chief Commercial Officer | 1976 |
| Glenn P. Brame | Chief Technical Operations Officer | 1957 |
| Benjamin O. Looker J.D. | Corporate Secretary, Chief Legal & Corporate Affairs Officer | 1982 |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | – |
| Betty Jean Swartz | Chief Business Officer | – |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 13. Jul 2026 | Hoffman Robert E. | Director | Other | 85,153 | – | – |
| 13. Jul 2026 | Carroll J Martin | Director | Other | 177,523 | – | – |
| 13. Jul 2026 | Shepard Jay | Director | Other | 164,472 | – | – |
| 13. Jul 2026 | Fischer Seth H. Z. | Director | Other | 141,023 | – | – |
| 13. Jul 2026 | Thompson John Craig | Director | Other | 79,873 | – | – |
| 13. Jul 2026 | Harlow John B. Jr. | Chief Commercial Officer | Other | 424,536 | – | – |
| 13. Jul 2026 | Looker Benjamin | Chief Legal Officer | Other | 667,524 | – | – |
| 13. Jul 2026 | Halladay Benjamin | Chief Financial Officer | Other | 705,410 | – | – |
| 13. Jul 2026 | Koenig Sheldon L. | President and CEO | Other | 2,121,094 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.